

*Election*

U.S. Serial No. 09/822,672

Atty Reference: 037003-0280062

Page 2

90. (New) The method of Claim 89 wherein said chimeric anti-CD20 antibody is RITUXAN®.

91. (New) The method of Claim 74 wherein said treating is combined with chemotherapy.

92. (New) The method of Claim 74 wherein said B cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL and Waldenstrom's Macroglobulinemia.

93. (New) The method of Claim 74 wherein said antibodies are administered by intravenous, intramuscular, intratumeoral or intraperitoneal administration.

94. (New) The method of Claim 91 wherein said chemotherapy is selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA (with or without subsequent G-CSF treatment), VAD, M&P, C-Weekly, ABCM, MOPP, DHAP, daunorubicin, doxorubicin, methotrexate, and cisplatin.

95. (New) The method of Claim 74 wherein either or both of said antibodies are human, humanized or chimeric antibodies.

96. (New) The method of Claim 74 wherein the dosage of said antibodies range from 0.01 to 1000 mg/kg body weight.